| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -6.9% | n/a |
| ROCE | n/a |
| Latest | F'cast | |
|---|---|---|
| P/E | n/a | n/a |
| PEG | n/a | n/a |
| Pr/Revenue | 2.7 | n/a |
| Pr/Book | 15.0 |
| Latest | F'cast | |
|---|---|---|
| Revenue | -28.3% | n/a |
| PBT | n/a | n/a |
| EPS | n/a | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 30-Nov-21 | 7.39 | (2.35) | (2.00)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Nov-22 | 8.17 | (2.72) | (1.51)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Nov-23 | 9.30 | (1.14) | (0.36)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Nov-24 | 12.04 | (0.03) | (0.01)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Nov-25 | 8.63 | (0.89) | (0.30)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Holding(s) in Company | 11-May-2026 | 13:53 | RNS |
| CEM Contract Win | 07-May-2026 | 07:00 | RNS |
| First order as Injectaclad supplier | 05-May-2026 | 07:00 | RNS |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 2.40p |
| Change Today | 0.100p |
| % Change | 4.35 % |
| 52 Week High | 6.45p |
| 52 Week Low | 1.03p |
| Volume | 8,296,920 |
| Shares Issued | 993.01m |
| Market Cap | £23.83m |
| Beta | 0.02 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:25 | 2,000 @ 2.50p |
| 16:18 | 160,965 @ 2.49p |
| 16:08 | 19,960 @ 2.49p |
| 15:57 | 8,587 @ 2.39p |
| 15:49 | 15,816 @ 2.49p |
| CEO | Simon Lincoln Deacon |
| COO | Andrew Mark Hempsall |
| CFO | James (Jim) Edward Snooks |
You are here: research